ACR16

DRUG2 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Huntington DiseaseHuntington's Disease

Phase 2

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

CompletedNCT00724048

Teva Branded Pharmaceutical Products R&D, Inc.Huntington Disease

Start: 2008-10-24End: 2010-07-26Updated: 2023-08-31

Phase 3

A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease

CompletedNCT00665223

Teva Branded Pharmaceutical Products R&D, Inc.Huntington's Disease

Start: 2008-04-24End: 2010-06-14Updated: 2023-08-29

Related Papers

Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose

Neurology and Therapy2023-02-223 citations

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.

2011-11-07124 citations